cardiotoxicity/väsimus

Link salvestatakse lõikelauale

Artiklid Kliinilistes uuringutesPatendid

Valige sortimise tüüp

Leht 1 alates 111 tulemused

Trastuzumab and doxorubicin-related cardiotoxicity and the cardioprotective role of exercise.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

Women diagnosed with breast cancer typically undergo a multimodal approach to treating their disease. The treatments used often result in sequelae such as fatigue, hair loss, nausea and vomiting, and functional impairment. Many of these sequelae can be controlled or eliminated with pharmacological,

Drug-induced cardiotoxicity due to aminophylline treatment: a case report.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

BACKGROUND Aminophylline, a theophylline compound that contains ethylenediamine, has untoward side effects on many organ systems. OBJECTIVE The goal of this case report was to illustrate the occurrence of acute adverse events (ie, chest discomfort and myocardial enzyme elevation) that may be

Doxorubicin cardiotoxicity: contractile changes after long-term treatment in the rat.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

Doxorubicin (DXR; Adriamycin) was administered i.v. to 20 Sprague-Dawley rats at 2.5 mg/kg once a week for 8 weeks. The rats were then observed for 2 to 5 weeks post treatment until they developed signs of general and cardiotoxicity (lassitude, ascites, marked ECG changes), at which time 11 of these

Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

BACKGROUND Anthracyclines are frequently used chemotherapeutic agents for childhood cancer that can cause cardiotoxicity during and after treatment. Although several medical interventions in adults with symptomatic or asymptomatic cardiac dysfunction due to other causes are beneficial, it is not

Crizotinib-induced cardiotoxicity: the importance of a proactive monitoring and management.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

Crizotinib is a multitarget tyrosine kinase inhibitor and it represents the standard of care in patients with anaplastic lymphoma kinase translocated non-small-cell lung cancer. Crizotinib is generally well tolerated and the most frequent adverse events include gastrointestinal effects, visual

Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

A phase 2 randomized trial to evaluate the impact of a supervised exercise program on cardiotoxicity at 3 months in patients with HER2 overexpressing breast cancer undergoing adjuvant treatment by trastuzumab: design of the CARDAPAC study.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

BACKGROUND The overexpression of human epidermal growth factor receptor-2 (HER2) in breast cancer is a poor prognosis. Trastuzumab improves overall survival but is associated with cardiotoxicity, especially a decline in left ventricular ejection fraction (LVEF). In addition, chemotherapy and

Direct effects of doxorubicin on skeletal muscle contribute to fatigue.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

Chemotherapy-induced fatigue is a multidimensional symptom. Oxidative stress has been proposed as a working mechanism for anthracycline-induced cardiotoxicity. In this study, doxorubicin (DOX) was tested on skeletal muscle function. Doxorubicin induced impaired ex vivo skeletal muscle relaxation

Impact of exercise training on cardiotoxicity and cardiac health outcomes in women with breast cancer anthracycline chemotherapy: a study protocol for a randomized controlled trial.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

Anthracyclines are chemotherapeutic agents frequently used in breast cancer (BC) treatment. Although it improves disease-free and overall survival, the use of anthracyclines is associated with a cumulative risk of cardiac toxicity. Preventive strategies to optimize cardiac health are

Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

OBJECTIVE This phase II study was undertaken to assess objective response and toxicity of histone deacetylase inhibitor depsipeptide in patients with neuroendocrine tumors. METHODS A total of 15 patients with metastatic neuroendocrine tumors received a 4-hour i.v. infusion of depsipeptide at 14

Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

OBJECTIVE Sunitinib is an oral multitargeted receptor tyrosine kinase inhibitor. The purpose of this study was to determine the recommended phase 2 dose, pharmacokinetics, pharmacodynamic effects, and preliminary antitumor activity of sunitinib in a pediatric population. METHODS Patients who were 2

Nursing implications in the administration of paclitaxel (TAXOL).

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

Paclitaxel is an antimicrotubule agent that was recently approved by the Food and Drug Administration (FDA). Because it is insoluble in water, it is mixed with Cremophor EL (polyoxyethylated castor oil). The addition of Cremophor requires the use of glass bottles or polyolefin or polypropylene bags

Pazopanib-induced fatal heart failure in a patient with unresectable soft tissue sarcoma and review of literature.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

Pazopanib, an oral multi-targeted tyrosine kinase inhibitor, is associated with improved outcomes in patients with unresectable or metastatic soft tissue sarcoma. Pazopanib may cause cardiotoxicity such as heart failure.A 50-year-old female patient with no

A phase I study of pazopanib in combination with escalating doses of 131I in patients with well-differentiated thyroid carcinoma borderline refractory to radioiodine.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

OBJECTIVE This trial was conducted to evaluate the ability of pazopanib to overcome therapeutic 131I resistance. UNASSIGNED This phase 1 trial assesses the combination of pazopanib and escalating doses of radioiodine (131I) in patients with recurrent or metastatic thyroid cancer that are borderline

Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

OBJECTIVE To determine the efficacy and safety profile, including the risk for cardiac toxicity, of liposome-encapsulated doxorubicin (TLC D-99), fluorouracil (5-FU), and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer (MBC). METHODS Forty-one women were

Eelmine
1
2
3
4
5
6
7
8
Järgmine

Liitu meie
facebooki lehega

Herbal & Natural Medicine

Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus

Töötab 55 keeles
Taimsed ravimid, mida toetab teadus
Maitsetaimede äratundmine pildi järgi
Interaktiivne GPS-kaart - märgistage ürdid asukohas (varsti)
Lugege oma otsinguga seotud teaduspublikatsioone
Otsige ravimtaimi nende mõju järgi
Korraldage oma huvisid ja hoidke end kursis uudisteuuringute, kliiniliste uuringute ja patentidega

Sisestage sümptom või haigus ja lugege ravimtaimede kohta, mis võivad aidata, tippige ürdi ja vaadake haigusi ja sümptomeid, mille vastu seda kasutatakse.
* Kogu teave põhineb avaldatud teaduslikel uuringutel